Cargando…

Specific Treatment Exists for SARS-CoV-2 ARDS

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manife...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanwar, Badar, Lee, Chul Joong, Lee, Jong-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229893/
https://www.ncbi.nlm.nih.gov/pubmed/34200720
http://dx.doi.org/10.3390/vaccines9060635
_version_ 1783713078156722176
author Kanwar, Badar
Lee, Chul Joong
Lee, Jong-Hoon
author_facet Kanwar, Badar
Lee, Chul Joong
Lee, Jong-Hoon
author_sort Kanwar, Badar
collection PubMed
description The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsone’s effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimer’s disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p < 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Bötzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2.
format Online
Article
Text
id pubmed-8229893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82298932021-06-26 Specific Treatment Exists for SARS-CoV-2 ARDS Kanwar, Badar Lee, Chul Joong Lee, Jong-Hoon Vaccines (Basel) Communication The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsone’s effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimer’s disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p < 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Bötzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2. MDPI 2021-06-10 /pmc/articles/PMC8229893/ /pubmed/34200720 http://dx.doi.org/10.3390/vaccines9060635 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Kanwar, Badar
Lee, Chul Joong
Lee, Jong-Hoon
Specific Treatment Exists for SARS-CoV-2 ARDS
title Specific Treatment Exists for SARS-CoV-2 ARDS
title_full Specific Treatment Exists for SARS-CoV-2 ARDS
title_fullStr Specific Treatment Exists for SARS-CoV-2 ARDS
title_full_unstemmed Specific Treatment Exists for SARS-CoV-2 ARDS
title_short Specific Treatment Exists for SARS-CoV-2 ARDS
title_sort specific treatment exists for sars-cov-2 ards
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229893/
https://www.ncbi.nlm.nih.gov/pubmed/34200720
http://dx.doi.org/10.3390/vaccines9060635
work_keys_str_mv AT kanwarbadar specifictreatmentexistsforsarscov2ards
AT leechuljoong specifictreatmentexistsforsarscov2ards
AT leejonghoon specifictreatmentexistsforsarscov2ards